Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria.

@article{Palmer2005IrbesartanIP,
  title={Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria.},
  author={A. Jay Palmer and Lieven Annemans and St{\'e}phane Roze and Pablo Lapuerta and Roland Chen and Sylvie Gabriel and Paulo Carita and Roger A. Rodby and Dick de Zeeuw and H H Parving and Fernando de {\'A}lvaro},
  journal={Kidney international. Supplement},
  year={2005},
  volume={93},
  pages={S52-4}
}
OBJECTIVES The purpose of this study was to project the cumulative incidence of end-stage renal disease (ESRD), life expectancy, and costs in a Spanish setting of treating patients with diabetes, hypertension, and microalbuminuria with either standard hypertension treatment alone or standard hypertension treatment plus irbesartan 300 mg daily. METHODS A peer-reviewed, published Markov model that simulated progression from microalbuminuria to nephropathy, doubling of serum creatinine, ESRD… CONTINUE READING